PropertyValue
?:abstract
  • Roche will pay Atea Pharmaceuticals $350 million for rights to develop and distribute AT-527, an experimental antiviral treatment, outside the US Before the COVID-19 pandemic, Atea had begun developing AT-527, a purine nucleotide prodrug, as an oral treatment for infections of hepatitis C virus The company is now testing the molecule, which interferes with viral RNA polymerase, in a clinical trial of people with mild to moderate COVID-19 Atea also granted Roche rights to manufacture AT-527 worldwide [ ]
is ?:annotates of
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Roche taps Atea for COVID-19 antiviral
?:type
?:who_covidence_id
  • #927216
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/4m1jmslc>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/4m1jmslc>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all